Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

# Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response..

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Ì	pe Response		•								la n		· cp		\ . ¥		
Name and Address of Reporting Person * Benaim Ely					2. Issuer Name <b>and</b> Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RN							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
•				3. Date of Earliest Transaction (Month/Day/Year) 01/26/2018 4. If Amendment, Date Original Filed(Month/Day/Year)							Director 10% Owner  X Officer (give title below) Other (specify below)  Chief Medical Officer						
											6. Iı	6. Individual or Joint/Group Filing(Check Applicable Line)					
ROCKVILLE, MD 20850				, (							_X_	X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities A							s Acquired	equired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year			2A. Deemed Execution Date, i ) any (Month/Day/Year		ate, if Co	(Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)  (A) or Amount (D)		of (D) Own				Ownership Form:	Beneficial Ownership		
	Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date,	(e.g., puts, calls 4. If Transaction Code r) (Instr. 8)		5. Numl of Derivati Securiti	s, warrants, of 5. Number of Derivative Securities		ired, Disposed of, or Ben options, convertible secure 6. Date Exercisable and Expiration Date (Month/Day/Year)			d f g	8. Price of Derivative Security (Instr. 5)	Securities Beneficially	Ownersh Form of Derivati	Beneficia Ownershi	
Title of Derivative			3A. Deemed	(e.g., put 4.	s, cal	ls, warra 5. Numl	ants,	ired, Dispoptions, c	oosed of, onvertib xercisabl	or Ben le secui	eficially Ov	<b>vned</b>		9. Number			
(max. 5)	Derivative Security						Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				(Instr. 3 and 4)		1.1	Owned Following Reported Transaction(s (Instr. 4)	Security Direct (I or Indire (S) (I) (Instr. 4)	) (	
				Code	V	(A)	(D)	Date Exercisal	Expir Date	ation	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$ 2.29	01/26/2018		A		45,443		<u>(1)</u>	01/20	6/2028	Commor Stock	45,443	\$ 0	45,443	D		
Repor	ting O	wners															
		NY / A 33				Relati	onsh	ips									
R	eporting Ov	vner Name / Addr	ess .	100/		OCC.				Other							

## **Signatures**

ROCKVILLE, MD 20850

Benaim Ely

/s/ Douglas J. Swirsky, as attorney-in-fact for Ely Benaim	01/30/2018		
**Signature of Reporting Person	Date		

### **Explanation of Responses:**

C/O REXAHN PHARMACEUTICALS, INC.

15245 SHADY GROVE ROAD, SUITE 455

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One quarter of the option vests and becomes exercisable on January 26, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested.

Chief Medical Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.